Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 1, 2026

Enterprise Software Leaders Build AI Agents With NVIDIA

View original at finance.yahoo.com
Enterprise Software Leaders Build AI Agents With NVIDIA NVIDIA Enterprise Software Leaders Build AI Agents With NVIDIANVIDIA today announced new software, open source models and partnerships with the world’s leading software platform providers to build autonomous AI agents for industries and enterprises across engineer…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Autonomous AI agents require a software layer called a harness to turn a model into an agent with functions like orchestration, context, memory, tool use and security

    60% confidence

  • NVIDIA Nemotron 3 Ultra delivers up to 30% lower cost for complex agentic tasks

    60% confidence

  • Cadence, Dassault Systèmes, Siemens and Synopsys are using NVIDIA NemoClaw to build autonomous AI engineers that compress weeks of engineering work into hours

    60% confidence

  • CrowdStrike and Palantir are transforming cybersecurity and operational decision-making with long-running AI agents powered by Nemotron open models, enabling teams to analyze data faster and streamline operations across complex environments

    60% confidence

  • NVIDIA Nemotron 3 Ultra delivers 5x faster inference for complex agentic tasks compared to prior models

    60% confidence

  • The world's software leaders are bringing AI agents into the systems where work gets done, showing how AI coworkers help employees think faster and execute complex tasks to solve bigger problems, and NVIDIA NemoClaw provides enterprise software developers with the open building blocks to create more secure long-running AI coworkers that amplify human expertise

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com